MASS
908 Devices Inc.
$11.51
+0.70% 2026-10-20
Healthcare
MASSSPY
1W
-4.8%
1M
+9.3%
3M
+56.6%
6M
+58.5%
YTD
+119.2%
1Y
+28.0%
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsNorth America Prefab Wood Building Market Size and Share - Forecast, 2026-2035 | Mass Timber and Modular Housing to Propel Market to USD 15.42 Billion by 2035
GlobeNewswire · 7h ago
A New Fake Store Every 3 Minutes: Scamwise Holiday Report Shows How AI Has Turned E-Commerce Scammers into Mass Retailers
GlobeNewswire · 16h ago
xMEMS Enters Mass Production of Solid-State Micro-Cooling Expanding Active Thermal Management Across Edge AI and Data Center Infrastructure
Business Wire · 18h ago
Fabarta Unveils Major Upgrade to Its AI4S Platform: RSI Engine Connects Materials Discovery, Digital Pilot-Scale Trials and Industrial Mass Production
PR Newswire · Oct 19
Europe Differential-Pressure Mass Flow Controller Market Size and Forecast, 2021 - 2031 | Green Hydrogen and Industry 4.0 Drive 3.4% CAGR and a US$27.4 Million Opportunity
GlobeNewswire · Oct 16
Key stats
Market cap$475.8M
P/E (trailing)–
P/E (forward)-37.4
52-week range5.03 – 13.35
Revenue growth (YoY, latest qtr)+23.3%
Dividend yield0.00%
Analyst consensusStrong Buy (4)
Mean price target$13.38 (+16%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
Leans expensive
Model read-out from the numbers below, not advice. Score -1 (DCF counts double).
▼DCF (base case)below the price by 76%
•Piotroski F-score4/9
•Altman Z2.4 (grey)
▲Analyst target+16% (4 analysts)
Discounted cash flow
Bear
$2
-79%
growth 9% · disc. 8.4% · term. 2.0%
Base
$3
-76%
growth 15% · disc. 7.4% · term. 2.5%
Bull
$3
-72%
growth 18% · disc. 6.4% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 49% a year for 10 years.
Implied
+49%/yr
FCF, last 3 yrs
n/a
FCF, last 5 yrs
n/a
Revenue, last 3 yrs
+6%/yr
Revenue, last 5 yrs
+16%/yr
Same inputs as the DCF above: trailing free cash flow 0.0B, 7.4% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.62 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-0.31 vs trailing $-0.94. Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
RPO
$21.7M
as of 2026-06-30
vs a year ago
+21%
YoY
× TTM revenue
0.36×
coverage
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Gross margin
52.2%
Operating margin
-64.0%
FCF margin
1.0%
Net margin
-57.0%
Return on equity
-27.3%
Return on invested capital
-76.4%
Net debt / EBITDA
–
Current ratio
2.7×
Interest cover
-193.7×
Cash conversion (OCF/NI)
–
Piotroski F-score 4/9 · last two fiscal years
✓ Positive net income✗ Positive operating cash flow✓ Return on assets improved✗ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✗ Asset turnover improved
Altman Z-score 2.4 (grey zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$13
+16%
Analysts
4
Strong Buy
Range
$12–$14
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $56.2M | $19.5M | $-24.6M |
| 2024 | $47.7M | $-72.2M | $-30.8M |
| 2023 | $50.2M | $-36.4M | $-27.1M |
| 2022 | $46.9M | $-33.6M | $-23.0M |
| 2021 | $42.2M | $-22.2M | $-29.8M |
| 2020 | $26.9M | $-12.8M | $4.1M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +6.2%.
Earnings
Next report: 2026-11-10 · before open · EPS est -0.10
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | -0.14 | -0.06 | +54.1% |
| 2026-05-06 | -0.14 | -0.07 | +46.9% |
| 2026-03-03 | -0.05 | 0.02 | +142.0% |
| 2025-11-10 | -0.11 | -0.04 | +61.7% |
| 2025-08-05 | -0.14 | -0.26 | -80.6% |
| 2025-05-13 | -0.27 | -0.19 | +30.9% |
| 2025-03-04 | -0.35 | -0.28 | +19.1% |
| 2024-11-12 | -0.29 | -0.31 | -6.3% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $16.1M | +23.3% |
| 2026-03-31 | $13.4M | – |
| 2025-12-31 | $17.4M | – |
| 2025-09-30 | $14.0M | – |
| 2025-06-30 | $13.0M | – |
Analyst actions
Canaccord Genuity
PT $14
2026-09-10 · init
→ BuyPT $14
Stifel
PT $12
2026-08-12 · main
Buy → BuyPT $12
Roth Capital
PT $13
2026-08-12 · main
Buy → BuyPT $13
Roth Capital
PT $11
2026-07-29 · init
→ BuyPT $11
Leerink Partners
PT $12
2025-08-05 · up
Market Perform → OutperformPT $12
Stephens & Co.
PT $6
2025-01-15 · reit
Overweight → OverweightPT $6
Insider trades
Brown Christopher D.
$356.7K
Director · 2026-10-07
SELL$356.7K
Griffith Joseph H. Iv
$65.2K
Chief Financial Officer · 2026-10-06
SELL$65.2K
Awm Investment Company, Inc.
$207.3K
10% owner · 2026-09-29
SELL$207.3K
Awm Investment Company, Inc.
$272.6K
10% owner · 2026-09-24
SELL$272.6K
Awm Investment Company, Inc.
$11.2K
10% owner · 2026-09-23
SELL$11.2K
Kenneweg John
$53.7K
SVP, Sales & Product Marketing · 2026-09-17
SELL$53.7K
Kenneweg John
$216.3K
SVP, Sales & Product Marketing · 2026-09-16
SELL$216.3K
Kenneweg John
$10.0K
SVP, Sales & Product Marketing · 2026-09-15
SELL$10.0K
Brown Christopher D.
$317.4K
Director · 2026-09-02
SELL$317.4K
Griffith Joseph H. Iv
$125.5K
Chief Financial Officer · 2026-08-25
SELL$125.5K
Awm Investment Company, Inc.
$441.2K
10% owner · 2026-08-21
SELL$441.2K
Awm Investment Company, Inc.
$88.6K
10% owner · 2026-08-20
SELL$88.6K
Stats refreshed 2026-10-20 18:13:52 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.